



Published in final edited form as:

J Alzheimers Dis. 2016 March 29; 52(3): 849–861. doi:10.3233/JAD-150900.

Cortical Amyloid Burden Differences Across Empirically-Derived Mild Cognitive Impairment Subtypes and Interaction with APOE ϵ 4 Genotype

Katherine J. Bangen^{a,b,*}, Alexandra L. Clark^{a,c}, Madeline Werhane^c, Emily C. Edmonds^{a,b}, Daniel A. Nation^d, Nicole Evangelista^{a,b}, David J. Libon^e, Mark W. Bondi^{a,b}, and Lisa Delano-Wood^{a,b} for the Alzheimer's Disease Neuroimaging Initiative¹

^aVeterans Affairs San Diego Healthcare System, San Diego, CA, USA

^bDepartment of Psychiatry, University of California, San Diego, La Jolla, CA, USA

^cSan Diego State University/University of California, San Diego (SDSU/UCSD) Joint Doctoral Program in Clinical Psychology, San Diego, CA, USA

^dDepartment of Psychology, University of Southern California, Los Angeles, CA, USA

^eDepartment of Neurology, Drexel University College of Medicine, Philadelphia, PA, USA

Abstract

We examined cortical amyloid- β (A β) levels and interactions with apolipoprotein (APOE) ϵ 4 genotype status across empirically-derived mild cognitive impairment (MCI) subgroups and cognitively normal older adults. Participants were 583 ADNI participants (444 MCI, 139 normal controls [NC]) with baseline florbetapir positron emission tomography (PET) amyloid imaging and neuropsychological testing. Of those with ADNI-defined MCI, a previous cluster analysis [1] classified 51% ($n = 227$) of the current sample as amnesic MCI, 8% ($n = 37$) as dysexecutive/mixed MCI, and 41% ($n = 180$) as cluster-derived normal (cognitively normal). Results demonstrated that the dysexecutive/mixed and amnesic MCI groups showed significantly greater levels of amyloid relative to the cluster-derived normal and NC groups who did not differ from each other. Additionally, 78% of the dysexecutive/mixed, 63% of the amnesic MCI, 42% of the cluster-derived normal, and 34% of the NC group exceeded the amyloid positivity threshold. Finally, a group by APOE genotype interaction demonstrated that APOE ϵ 4 carriers within the amnesic MCI, cluster-derived normal, and NC groups showed significantly greater amyloid accumulation compared to non-carriers of their respective group. Such an interaction was not revealed within the dysexecutive/mixed MCI group which was characterized by both greater cognitive impairment and amyloid accumulation compared to the other participant groups. Our results from the ADNI cohort show considerable heterogeneity in A β across all groups studied,

*Correspondence to: Katherine Bangen, PhD, 9500 Gilman Drive, Mail Code 151B, San Diego, CA 92093-9151, USA. Tel.: +1 858 552 8585/Ext: 5794; Fax: +1 858 642 6340; ; Email: kbangen@ucsd.edu

¹Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (<http://adni.loni.usc.edu>). As such, the investigators within the ADNI contributed to the design and implementation of the ADNI and/or provided data but did not participate in analysis or writing of this article. A complete listing of ADNI investigators can be found at http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf.

Authors' disclosures available online (<http://www.j-alz.com/manuscript-disclosures/15-0900r1>).

even within a group of robust NC participants. Findings suggest that conventional criteria for MCI may be susceptible to false positive diagnostic errors, and that onset of A β accumulation may occur earlier in APOE ϵ 4 carriers compared to non-carriers.

Keywords

Amyloid; apolipoprotein E; APOE; biomarkers; florbetapir; mild cognitive impairment; neuroimaging; neuropsychology; PET; positron emission tomography

INTRODUCTION

Identification of risk factors and prevention targets for Alzheimer's disease (AD) has become a critical public health concern given its rapidly increasing prevalence [2, 3] coupled with the overwhelming failure of clinical trials designed to modify risk [4]. Embedded within this initiative is the need to accurately characterize mild cognitive impairment (MCI), an at-risk state that represents the transitional stage between normal aging and dementia [5–8]. While advances in research of neuroimaging and biofluid markers have improved our ability to detect and diagnose AD [9] and its preceding stages [10, 11], research focused on profiling mild forms of cognitive impairment have failed to reach this same level of sophistication. As a result, proper characterization of MCI has become a point of significant concern and controversy in both clinical and research settings [12].

Presently, MCI is commonly defined by objective evidence for cognitive impairment (i.e., performance less than or equal to 1.5 standard deviations below the normative mean on at least one neuropsychological measure), along with a subjective memory complaint, that occurs in the context of preserved overall cognition and ability to perform tasks of daily living [7, 8, 13]. Unfortunately, the application of these MCI criteria often involve: (1) crude cognitive screening measures rather than validated neuropsychological assessments that are more sensitive and specific to cognitive impairment; (2) subjective clinical judgment, in contrast to objective diagnostic decision-making; and (3) limited assessment protocols that fail to adequately tap domains of cognition outside of memory ability.

Recent research has provided a data-driven, empirical method of deriving MCI subtypes by using cluster analytic statistical techniques [1, 14–18]. Such studies have demonstrated that individuals with MCI can be meaningfully grouped together based on similarities in their patterns of performance across multiple cognitive domains. This research has revealed multiple subtypes of MCI, provided more nuanced MCI distinctions, and shown tighter associations with respect to biomarkers related to cognitive impairment as well as progression to dementia [1]. Additionally, recent research has demonstrated significant heterogeneity in MCI [14, 15, 19], considerable instability regarding the diagnosis of MCI, and highly variable prevalence rates across studies [20, 21]. All of this work has fueled efforts to improve the diagnostic rigor for MCI through employment of actuarial decision-making using a full range of neuropsychological test measures [20, 22, 23]. Such studies have consistently found evidence for distinct MCI phenotypic subgroups; however, one of the most provocative findings that has emerged from research employing actuarial decision-making has been the identification of a cluster-derived normal group which consists of a

large subset of individuals originally diagnosed with MCI but who performed within normal limits upon cognitive testing [1, 17, 18]. This “false positive” subgroup [1, 18] performs similarly to normal control (NC) participants on tests of cognition and show comparable cortical thickness values in areas typically affected by MCI and AD (Edmonds et al., under review). Additionally, cerebrospinal fluid (CSF) AD biomarker profiles do not differ between these groups. Moreover, as compared to other MCI subtypes, the cluster-derived normal group demonstrate an overall lower genetic risk for AD and contain fewer individuals who eventually progressed to dementia [1, 17, 18].

We aimed to extend our previous findings by examining levels of cortical amyloid- β ($A\beta$), an AD hallmark protein currently being targeted in clinical trials of disease-modifying agents in early AD, across empirically-derived MCI and cognitively normal subgroups. We examined group differences in mean cortical and regional amyloid load measured by florbetapir F 18 positron emission tomography (PET) imaging. Given the role of apolipoprotein E (APOE) in $A\beta$ accumulation [24], we also examined the extent to which APOE $\epsilon 4$ status (carrier versus non-carriers) influences amyloid accumulation within the cognitive groups. Based on our previous findings described above, we expected to find differences in cortical amyloid accumulation between empirically-derived MCI subgroups and cognitively normal groups, but no such differences between the cluster-derived normal and NC groups. In addition, we expected a cognitive group by APOE interaction whereby $\epsilon 4$ carriers would demonstrate greater amyloid burden compared to non-carriers across the participant groups.

MATERIALS AND METHODS

The ADNI dataset

Data used for this study were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (<http://adni.loni.usc.edu>). The ADNI was launched in 2003 by the National Institute on Aging (NIA), the National Institute of Biomedical Imaging and Bioengineering (NIBIB), the Food and Drug Administration (FDA), private pharmaceutical companies and non-profit organizations, as a \$60 million, 5-year public-private partnership. The primary goal of ADNI has been to test whether serial magnetic resonance imaging (MRI), PET, other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of MCI and early AD. The Principal Investigator of this initiative is Michael W. Weiner, MD, VA Medical Center and University of California – San Francisco. ADNI is the result of efforts of many coinvestigators from a broad range of academic institutions and private corporations, and subjects have been recruited from over 50 sites across the U.S. and Canada. The initial goal of ADNI was to recruit 800 subjects but ADNI has been followed by ADNI-GO and ADNI-2. Subjects originally recruited for ADNI-1 and ADNI-GO had the option to be followed in ADNI-2. For up-to-date information, see <http://www.adni-info.org>.

Participants

Participants were 583 older adults who completed a comprehensive neuropsychological assessment and baseline florbetapir PET scan with processed data available for download as of December 2015 and also had available apolipoprotein (APOE) genotype data. This

included 444 individuals diagnosed with MCI and 139 cognitively normal older adults. Full criteria for ADNI eligibility and diagnostic classifications are described in detail at <http://www.adni-info.org>.

ADNI diagnostic criteria for MCI were as follows: (1) subjective memory complaints reported by participants, a study partner, or clinician, (2) objective memory loss defined as scoring below an education-adjusted cut-off score on delayed recall of Story A of the WMS-R Logical Memory Test, (3) global Clinical Dementia Rating (CDR) scale score of 0.5, and (4) general cognitive and functional performance sufficiently preserved such that a diagnosis of dementia could not be made by the site physician at the time of screening. The cognitively normal group for the present study included all participants who had at least one year of follow-up and who remained classified as normal throughout their participation in ADNI (range of 1–3 years of follow-up).

Empirically-derived MCI subtypes

We previously performed a cluster analysis using six neuropsychological scores from 846 MCI participants diagnosed using ADNI criteria [1]. The current study includes individuals from this initial sample who underwent florbetapir PET imaging at their baseline exam. The clusters derived in this initial study were used in the current study given that the cluster solution from the larger sample was more reliable. The cluster analysis methods used in this initial study have been previously described [1]. Briefly, a cluster analysis was performed using the following six measures of cognition: 1) Animal Fluency, total score; 2) 30-item Boston Naming Test (BNT) total score; 3) Trail Making Test, Part A; time to completion, 4) TMT, Part B; time to completion, 5) Rey Auditory Verbal Learning Test (AVLT) 30-minute delayed free recall; number of words recalled, and 6) AVLT recognition; number of words correctly recognized. These measures were selected because of their routine use in assessing early cognitive changes in AD, they were administered to all participants, and they assessed three different domains of cognitive ability – language (Animal Fluency, BNT), speed/executive function (Trail Making Test, Parts A and B), and episodic memory (AVLT recall & recognition).

Previous analyses revealed a three-cluster solution in which (1) amnesic MCI ($n = 477$), (2) dysexecutive/mixed MCI ($n = 104$), and (3) cluster-derived normal ($n = 265$) subgroups were identified [1]. The amnesic MCI subgroup demonstrated mildly impaired performance on memory measures (Rey AVLT delayed recall and recognition). The dysexecutive/mixed MCI subgroup performed in the severely impaired range on tasks of speed/executive function (Trail Making Test, Parts A and B) and had mildly impaired memory (Rey AVLT delayed recall and recognition) and language scores (BNT and Animal Fluency). Finally, the cluster-derived normal subgroup performed within normal limits across all six neuropsychological measures. For the present study, using cluster analysis, 51% ($n = 227$) of the current sample were classified as amnesic MCI, 8% ($n = 37$) dysexecutive/mixed MCI, and 41% ($n = 180$) belonged to the cluster-derived normal group. Fig. 1.

Clinical outcome

Participants had follow-up examinations (up to 3 years) following baseline assessment. Clinical out-comes were operationalized as: (1) “No change” for MCI participants who remained diagnosed as MCI; (2) “Reversion” for MCI participants who reverted back to a cognitively normal diagnosis on subsequent examination; and (3) “Progression” for MCI participants who progressed to a diagnosis of AD on subsequent examination.

Florbetapir PET data acquisition and processing

All participants underwent florbetapir PET imaging within two weeks of their baseline neuropsychological assessments. A detailed description of ADNI florbetapir PET imaging data acquisition and processing can be found online (http://adni.loni.usc.edu/wp-content/uploads/2010/05/ADNI2_PET_Tech_Manual_0142011.pdf; <http://adni.loni.usc.edu/methods/pet-analysis/pre-processing/>). Briefly, florbetapir scans were reviewed for quality control before being co-registered, averaged, reoriented into a standard $160 \times 160 \times 96$ voxel image grid with 1.5 mm cubic voxels, and smoothed to a uniform isotropic resolution of 8 mm full width at half maximum. Structural MR images were skull-stripped, segmented, parcellated using Freesurfer and subsequently co-registered to each participants' first florbetapir image.

The florbetapir mean of each subregion was weighted by its volume to account for difference in sizes of the subregions. The four regions of interest (ROI) were: (1) frontal, (2) anterior/posterior cingulate, (3) lateral parietal, and (4) lateral temporal cortex. A florbetapir mean cortical summary standardized uptake value ratio (SUVR) was calculated by averaging across the four main cortical regions and dividing by the mean florbetapir value of the whole cerebellum (white and gray matter). In addition, SUVRs for each of the four regions was calculated by dividing by the mean of that individual region by the mean for the whole cerebellum. Increased retention of florbetapir is thought to reflect increased cortical amyloid load. Amyloid positivity versus negativity was determined based on the recommended threshold for cross-sectional florbetapir analyses of 1.11 using the whole cerebellum as the reference region [25, 26].

Statistical analyses

A series of analysis of variance (ANOVAs) and analysis of covariance (ANCOVAs) adjusted for age and APOE genotype were performed to compare participant groups in terms of demographics, neuropsychological performance, and florbetapir SUVRs. Chi-square analyses were conducted to statistically compare the participants groups in terms of frequencies of APOE genotype ($\epsilon 4$ carrier versus noncarriers), A β threshold positivity, and clinical outcomes (no change versus reversion versus progression). Additional ANCOVAs adjusted for age were conducted to examine the interaction of diagnostic group and APOE $\epsilon 4$ status (carrier versus non-carrier) on amyloid burden. Bonferroni-corrected *post hoc* tests were conducted for significant omnibus tests ($\alpha = 0.05/6 = 0.008$). Logistic regression (adjusted for age, APOE genotype, and length of follow up) were conducted to assess the association between baseline amyloid burden and longitudinal clinical outcome. All analyses were performed in SPSS (version 20).

RESULTS

Characteristics of the MCI cluster and normal control groups

Participant demographics are presented in Table 1. ANOVA revealed that the 4 groups significantly differed in terms of age ($p < 0.001$). *Post hoc t*-tests revealed the dysexecutive/mixed MCI and NC groups were both significantly older than the cluster-derived normal group (p 's < 0.008). The groups significantly differed regarding APOE genotype ($\epsilon 4$ carriers versus non-carriers; $p < 0.001$), and *post-hoc* chi-square tests revealed that the amnesic MCI group had a greater proportion of APOE $\epsilon 4$ carriers in comparison to the NC ($p < 0.001$) and cluster-derived normal ($p = 0.004$) groups. The dysexecutive/mixed MCI group had a greater proportion of APOE $\epsilon 4$ carriers relative to the NC ($p < 0.001$) group. There were no significant group differences with respect to education ($p = 0.057$) or sex ($p = 0.058$).

Amyloid positivity across the MCI cluster and normal control groups

Overall, 50% ($n = 294$) of the entire sample met criteria for amyloid positivity and the proportion of individuals who met this diagnostic threshold significantly differed ($p < 0.001$) across the groups (Fig. 2). *Post hoc* chi-square tests showed that both the amnesic and dysexecutive/mixed MCI groups demonstrated a greater proportion of individuals who met criteria for amyloid positivity relative to both the NC (p 's < 0.001) and cluster-derived normal (p 's < 0.001) groups. The proportion of individuals who met criteria for amyloid positivity did not significantly differ between the amnesic and dysexecutive/mixed MCI groups ($p = 0.069$) or between the cluster-derived normal and NC groups ($p = 0.152$).

Cortical amyloid accumulation in the MCI cluster and normal control groups

ANCOVAs controlling for age and APOE genotype revealed that mean cortical florbetapir SUVR and regional amyloid accumulation (in frontal, temporal, cingulate, and parietal cortices) significantly differed across the groups (all p 's < 0.001 ; Table 1 and Figs. 3 and 4). With respect to mean cortical amyloid, *post hoc t*-tests showed that on average the dysexecutive/mixed MCI group had significantly greater amyloid burden ($p = 0.001$) than the amnesic MCI group; moreover, both the dysexecutive/mixed and amnesic MCI groups had significantly greater amyloid relative to the cluster-derived normal (p 's < 0.001) and NC (p 's < 0.001) groups. However, no significant differences were observed between the cluster-derived normal and NC groups ($p = 0.236$).

With respect to regional amyloid, *post hoc t*-tests revealed the following: (1) there were no significant differences between the dysexecutive/mixed and amnesic MCI groups ($p > 0.008$) in cingulate amyloid; however, frontal, parietal, and temporal amyloid burden was significantly greater in the dysexecutive/mixed MCI group relative to the amnesic MCI group (p 's < 0.008); (2) both MCI groups displayed significantly greater frontal, cingulate, parietal, and temporal amyloid accumulation relative to NC (p 's < 0.008) and cluster-derived normal groups (p 's < 0.008); and (3) across all ROIs investigated, there were no significant difference in amyloid burden between the NC and cluster-derived normal groups (p 's > 0.170).

Interaction between cognitive group and APOE genotype on amyloid accumulation

ANCOVAs adjusting for age demonstrated that there was a significant Group \times APOE $\epsilon 4$ status interaction for mean cortical mean florbetapir SUVR ($F(3,574) = 3.98, p = 0.008, \eta_p^2 = 0.020$) and regional frontal ($F(3,574) = 4.56, p = 0.004, \eta_p^2 = 0.023$), cingulate ($F(3,574) = 4.23, p = 0.006, \eta_p^2 = 0.022$), parietal ($F(3,574) = 3.12, p = 0.026, \eta_p^2 = 0.016$), and temporal ($F(3,574) = 3.33, p = 0.019, \eta_p^2 = 0.017$) SUVRs (Fig. 5). Examination of simple main effects with Bonferroni correction revealed that, across all regions, APOE $\epsilon 4$ carriers within the amnesic MCI and cluster-derived normal groups had on average significantly greater amyloid accumulation in mean cortical and regional frontal, cingulate, parietal, and temporal cortices (all p 's < 0.001) when compared to APOE $\epsilon 4$ non-carriers of their respective group. Similarly, APOE $\epsilon 4$ carriers of the NC group had on average significantly greater mean cortical and regional frontal and cingulate (p 's < 0.008) amyloid accumulation compared to non-carriers of the same group. Within the dysexecutive/mixed MCI group, amyloid accumulation of APOE $\epsilon 4$ carriers did not significantly differ from non-carriers across any cortical ROI (all p 's > 0.008).

Clinical outcome by cognitive group and amyloid accumulation

Longitudinal data (mean follow-up = 13.9 months; range 6–36 months) were available for 91.7% of the MCI sample. Overall, 10.1% of those diagnosed with MCI progressed to AD and 3.9% reverted back to a cognitively normal classification. The NC group was not included in these analyses given that they were selected on the basis of remaining cognitively normal (did not progress to MCI) throughout the course of their ADNI participation.

A chi-squared analysis revealed that the groups (i.e., amnesic MCI, dysexecutive/mixed MCI, cluster-derived normal) significantly differed in diagnostic status (i.e., MCI to AD [progression], MCI to cognitively normal [reversion], or no change) at follow-up assessment ($\chi^2 = 37.97, p < 0.001$). The groups significantly differed in frequency of progression to AD (see Table 1) with the dysexecutive/mixed MCI group showing the highest rate of progression to dementia (30.6%) compared to the amnesic MCI (13.5%) and cluster-derived normal groups (1.2%). Logistic regressions, adjusting for age, APOE genotype, and length of follow-up, revealed greater baseline mean cortical florbetapir SUVR was associated with later progression to dementia ($\chi^2 = 11.39, p = 0.001$; mean cortical SUVR: $B = 2.93, p = 0.001$). When regional florbetapir SUVRs were assessed separately, baseline SUVRs for frontal, cingulate, parietal, and temporal cortices were significantly associated with later progression to dementia (p 's < 0.003).

DISCUSSION

Empirically-derived MCI subtypes from the ADNI cohort demonstrated considerable heterogeneity in A β accumulation as assessed by florbetapir PET. The cluster-derived normal group, all of whom were diagnosed as having MCI via ADNI protocols, did not differ from the NC group in terms of cortical florbetapir SUVRs. These results extend our previous finding of equivalence between cluster-derived normal and NC groups on AD biomarkers including CSF concentrations of hyperphosphorylated tau (p-tau_{181p}), A β ₁₋₄₂,

and the ratio of p-tau_{181p}/A β ₁₋₄₂ [18]; and frequency of the APOE ϵ 4 allele [1, 18] to PET A ϵ . Our present findings provide further support for the notion that conventional criteria for MCI may be susceptible to false positive diagnostic errors. In addition, even after adjusting for age and APOE genotype, MCI participants who were more severely cognitively impaired (i.e., showed impairments in multiple domains) demonstrated greater PET A β accumulation compared to the amnesic MCI, cluster-derived normal, and NC groups. This pattern of findings suggests that empirically-derived neuropsychological phenotypes correspond to differences in underlying fibrillar amyloid plaque density.

Our findings showed a pattern of progressive increase in A β positivity from 34% in cognitively normal older adults to 62% in amnesic MCI to 78% in dysexecutive/mixed MCI. The dysexecutive/mixed MCI showed greater A β accumulation in AD-vulnerable temporal and parietal regions relative to the amnesic MCI subgroup. The amnesic MCI subgroup demonstrated mildly impaired performance only on memory measures whereas the dysexecutive/mixed MCI subgroup performed in the severely impaired range on tasks of speed/executive function along with mild impairment on memory and language tests. Although this pattern of findings suggests that MCI represents a risk state for AD generally, it also further underscores the inherent heterogeneity within the ADNI MCI cohort. Indeed, approximately 40% and 20% of the amnesic and dysexecutive/mixed MCI participants, respectively, showed no evidence of A β positivity on florbetapir PET imaging suggesting that A β may be adding to or synergizing with other pathologies to produce progressive impairment.

An important finding in the current research is the presence of a cognitive group \times APOE genotype interaction on A β accumulation. Among the amnesic MCI, cluster-derived normal, and NC groups, APOE ϵ 4 carriers had higher levels of cortical A β relative to non-carriers in their respective groups. In contrast, among individuals with dysexecutive/mixed MCI, there was no difference in cortical A β level between APOE ϵ 4 carriers and non-carriers. Although we do not have information about the onset of cognitive impairment among our MCI participants, the dysexecutive/mixed MCI group demonstrated greater A β accumulation, was more cognitively impaired at baseline, had a higher mean age at baseline (although this difference was not statistically significant), and was more likely to convert to dementia than the other MCI subgroups and, therefore, may have been farther along in the disease course than the other groups.

Previous studies suggest that, among APOE ϵ 4 carriers, there may be earlier onset of cortical A β accumulation compared to non-carriers [27–29]. A recent meta-analysis showed that compared to the APOE ϵ 3 allele, the APOE ϵ 4 allele is associated with amyloid positivity among cognitively normal older adults [30]. Previous studies demonstrated that the presence of the APOE ϵ 4 allele was significantly associated with higher PET-Pittsburgh compound B (PiB) retention independent of age and sex, however, APOE genotype did not affect A β change over time [29]. This pattern of findings raises the possibility that APOE ϵ 4 carriers may be farther along in the disease process, consistent with earlier onset of brain A β accumulation and providing a neurobiological basis for the effects of APOE genotype on the age of onset in AD [29]. Weak associations between cognitive decline and change in A β over time may suggest that other non-amyloid pathologies (e.g., cerebrovascular disease) or other

downstream factors may have a more direct effect on cognition as the disease progresses [31].

Although caution must be taken given the cross-sectional design of the current study, our findings of greater A β accumulation among APOE ϵ 4 carriers compared to non-carriers in the amnesic MCI, cluster-derived normal, and NC groups coupled with no APOE genotype-related differences in A β accumulation in the dysexecutive/mixed MCI subgroup which showed the greatest A β accumulation and greatest cognitive impairment may support these previous studies indicating early onset of A β accumulation among APOE ϵ 4 carriers. Another possibility is that early in the disease course, among APOE ϵ 4 carriers, A β may play a larger role in symptom development compared to non-carriers who may have other non-amyloid pathologies (e.g., cerebrovascular disease) and for whom the early disease process may not necessarily involve amyloid to as great of an extent. When A β burden increases among APOE ϵ 4 non-carriers, cognitive decline may progress leading to more severe cognitive impairment and greater breadth of cognitive domains affected.

Neuropathological and multimodal clinical studies have shown that clinically diagnosed MCI and even amnesic MCI specifically [32, 33], is a pathologically heterogeneous disorder. The etiology of cognitive impairment in A β -negative individuals with MCI may relate to age-related pathologies including cerebrovascular disease, hippocampal sclerosis, Lewy body disease, or mixed pathologies [30, 32, 34]. This possibility is further underscored by a recent meta-analysis that showed that roughly 12% of clinically diagnosed AD participants showed a negative amyloid PET scan [34]. This finding may be explained by a mix of age-related pathologies, such as hippocampal sclerosis, argyrophilic grain disease, or tangle predominant dementia, that target the limbic system and may result in an “AD phenotype” predominated by memory impairment [34], or by co-occurring cerebrovascular disease. In a sample of autopsy-confirmed AD patients, we found that the presence of even mild cerebrovascular disease was associated with lower Braak stage, yet there were no differences in severity of cognitive impairment between the AD patients with and without cerebrovascular changes [35]. The fact that the AD patients with cerebrovascular disease showed the same degree of cognitive impairment as the AD patients without cerebrovascular disease, despite having a significantly lower burden of AD pathology, suggests that vascular pathology may have an additive effect on cognitive impairment, even in patients with autopsy-confirmed AD and relatively mild cerebrovascular disease [35].

Interestingly, more than a third of our rigorously screened, stable NC group who did not progress to MCI over 1–3 years of follow-up met criteria for A β positivity. Conversely, roughly 20% of our most impaired sample (those with prominent memory and executive dysfunction) did not meet the threshold for A β positivity. These findings further underscore recent work that has called into question the amyloid cascade hypothesis [36, 37]. Specifically, our results dovetail with neuropathological studies that have demonstrated that 33–50% of individuals without cognitive impairment show a significant amount of AD pathology at autopsy [38–41], and 10–30% of cognitively normal participants have considerably high brain levels of A β (PiB and florbetapir studies) [42, 43]. Importantly, the overall burden of amyloid in the AD brain is not associated with the severity of cognitive

decline [44–46], and amyloid plaques are not situated near neurons or synapses that degenerate in early AD [47]. Although clearly an important component that contributes to the disease process in AD, the pathogenesis of amyloid and how it relates to the clinical expression of AD is complex and unfortunately still very unclear. However, our current finding of a cognitive group \times APOE genotype interaction on A β accumulation taken together with previous studies demonstrating that the presence of the $\epsilon 4$ allele relates to earlier onset of disease [29] suggests that APOE genotype may influence the onset/course of disease. Nonetheless, the amyloid hypothesis is rapidly coming under increasing scrutiny as more clinical trials continue to fail in the face of new data that are not consistent with the hypothesis [36]. Clearly, additional studies examining the complex interaction of amyloid accumulation, synaptic loss, neurofibrillary tangle formation and accumulation, neurodegeneration, and microglial activation are needed in order to understand this complex disease and therefore lead to improved therapeutic strategies to combat AD.

A recent meta-analysis demonstrated that the age-related prevalence of amyloid positivity in cognitively normal individuals parallels the age-related prevalence of AD in the general population in APOE genotype specific patterns with a 20–30 year lag [30]. Given this pattern, Jansen and colleagues speculate that there may be 20–30 years between amyloid positivity and the expression of clinical AD [30]. Participants in the current study had follow-up between one and three years and, therefore, if they had been followed for a longer period of time, some of these individuals may have developed clinical AD. However, these participants demonstrated normal cognition in the context of significant burden of amyloid pathology suggesting that other factors, at least in a sizable proportion of older adults, likely contribute to the expression of cognitive impairment. Indeed, a recent study demonstrated that hippocampal volume and memory abilities are decoupled from amyloid burden in cognitively normal individuals with reductions in hippocampal volume and worsening memory occurring at earlier ages than abnormal PET amyloid [48]. Alternatively, although groups were similar on educational attainment, perhaps many of these individuals were able to benefit from greater levels of cognitive or neural reserve so that a greater burden of AD pathology was not coupled with overt cognitive decline [39, 49].

Our previous work suggests that a significant proportion of individuals in the ADNI MCI sample are cognitively normal once detailed testing and a more sensitive and reliable diagnostic scheme is employed [1, 18]. Our current findings indicate that these individuals do not differ from a robust normal control sample in terms of A β accumulation, further supporting the notion that these individuals likely do not represent prodromal AD. False positive diagnostic errors may have adverse consequences not only for those individuals from a clinical perspective, but they may negatively impact outcomes of biomarker studies and clinical trials. If a large number of cognitively normal older adults without significant amyloidosis or neurodegeneration are incorrectly classified as having MCI in studies of potential biomarkers or potential treatments, results could be significantly diluted and the apparent utility of these markers or treatments could be greatly diminished. Of course, an alternative strategy of recruitment based on amyloid positivity, as in the current A4 trial [50], will continue to miss many individuals as well, given the significant percentages of individuals with MCI without amyloid positivity, as shown in our study.

Strengths of this study include a large, well-characterized sample of older adults who have been followed longitudinally as part of a national study on aging and AD. Additionally, we employed an empirical data-driven statistical approach to the identification of MCI phenotypes, and use of a robust control group that excluded individuals with pre-clinical dementia at any time point of follow-up. A limitation of our study is the absence of assessing other cognitive domains, such as visuospatial functions, particularly since we have previously identified a visuospatial MCI subtype [17] and baseline MCI diagnoses based on visuospatial deficits reliably predict development of dementia with Lewy bodies [51]. The follow-up period was relatively short (up to 3 years) and the shorter follow-up time may explain the lower frequency of conversion from MCI to dementia in our current study compared to our previous studies that involved up to 7 years of follow-up [1, 18]. Although our observed MCI-to-dementia conversion rate of 10.1% over a mean follow-up of 13.9 months is relatively similar to the 12% annual conversion rate reported in the literature [13], future studies should aim for a longer follow-up period. Another limitation of our study is our inability to assess false negative diagnostic errors given our decision to use a ‘robust’ normal control sample. That is, individuals misclassified as cognitively normal but found to have cognitive impairment upon more extensive neuropsychological testing or who later declined were not included in the cognitively normal sample. In addition, given the relatively small number of participants in some subgroups (i.e., dysexecutive/mixed MCI) taken together with the low frequency of APOE $\epsilon 4$ homozygosity, we were unable to examine gene-dose effects. Future studies should explore whether incorporating more or different neuropsychological measures modifies cluster solutions and identifies additional individuals at risk for progression to AD. Future work should also incorporate novel tau tracers to assess both amyloidosis and neurodegeneration measured by PET. Improved diagnostic accuracy and characterization of prodromal AD phenotypes will assist clinicians and researchers in identifying those individuals who will develop AD. This work has important implications for biomarker studies, clinical trials, and treatment.

Acknowledgments

This work was supported by VA Clinical Science Research & Development (Career Development Award-2 I1K2CX000938 to KB), NIH grants (R01 AG012674 and K24 AG026431 to MB), and the Alzheimer’s Association (NIRG-13-281806 to LDW). Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare;; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (<http://www.fnih.org>). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.

References

1. Bondi MW, Edmonds EC, Jak AJ, Clark LR, Delano-Wood L, McDonald CR, Nation DA, Libon DJ, Au R, Galasko D, Salmon DP. Neuropsychological criteria for mild cognitive impairment improves diagnostic precision, biomarker associations, and progression rates. *J Alzheimers Dis.* 2014; 42:275–289. [PubMed: 24844687]
2. Alzheimer's Association. 2015 Alzheimer's disease facts and figures. *Alzheimers Dement.* 2015; 11:332–384. [PubMed: 25984581]
3. Matthews FE, Arthur A, Barnes LE, Bond J, Jagger C, Robinson L, Brayne C. A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: Results of the Cognitive Function and Ageing Study I and II. *Lancet.* 2013; 382:1405–1412. [PubMed: 23871492]
4. Cummings JL, Morstorf T, Zhong K. Alzheimer's disease drug-development pipeline: Few candidates, frequent failures. *Alzheimers Res Ther.* 2014; 6:37. [PubMed: 25024750]
5. Flicker C, Ferris SH, Reisberg B. Mild cognitive impairment in the elderly: Predictors of dementia. *Neurology.* 1991; 41:1006–1009. [PubMed: 2067629]
6. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: Clinical characterization and outcome. *Arch Neurol.* 1999; 56:303–308. [PubMed: 10190820]
7. Petersen RC, Morris JC. Mild cognitive impairment as a clinical entity and treatment target. *Arch Neurol.* 2005; 62:1160–1163. discussion 1167. [PubMed: 16009779]
8. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Nordberg A, Backman L, Albert M, Almkvist O, Arai H, Basun H, Blennow K, de Leon M, DeCarli C, Erkinjuntti T, Giacobini E, Graff C, Hardy J, Jack C, Jorm A, Ritchie K, van Duijn C, Visser P, Petersen RC. Mild cognitive impairment—beyond controversies, towards a consensus: Report of the International Working Group on Mild Cognitive Impairment. *J Intern Med.* 2004; 256:240–246. [PubMed: 15324367]
9. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement.* 2011; 7:263–269. [PubMed: 21514250]
10. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement.* 2011; 7:270–279. [PubMed: 21514249]
11. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH. Toward defining the pre-clinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement.* 2011; 7:280–292. [PubMed: 21514248]
12. Petersen RC, Caracciolo B, Brayne C, Gauthier S, Jelic V, Fratiglioni L. Mild cognitive impairment: A concept in evolution. *J Intern Med.* 2014; 275:214–228. [PubMed: 24605806]
13. Petersen RC. Mild cognitive impairment as a diagnostic entity. *J Intern Med.* 2004; 256:183–194. [PubMed: 15324362]
14. Delano-Wood L, Bondi MW, Sacco J, Abeles N, Jak AJ, Libon DJ, Bozoki A. Heterogeneity in mild cognitive impairment: Differences in neuropsychological profile and associated white matter lesion pathology. *J Int Neuropsychol Soc.* 2009; 15:906–914. [PubMed: 19891820]
15. Libon DJ, Xie SX, Eppig J, Wicas G, Lamar M, Lippa C, Bettcher BM, Price CC, Giovannetti T, Swenson R, Wambach DM. The heterogeneity of mild cognitive impairment: A neuropsychological analysis. *J Int Neuropsychol Soc.* 2010; 16:84–93. [PubMed: 19887015]

16. Eppig J, Wambach D, Nieves C, Price CC, Lamar M, Delano-Wood L, Giovannetti T, Bettcher BM, Penney DL, Swenson R, Lippa C, Kabasakalian A, Bondi MW, Libon DJ. Dysexecutive functioning in mild cognitive impairment: Derailment in temporal gradients. *J Int Neuropsychol Soc.* 2012; 18:20–28. [PubMed: 22014116]
17. Clark LR, Delano-Wood L, Libon DJ, McDonald CR, Nation DA, Bangan KJ, Jak AJ, Au R, Salmon DP, Bondi MW. Are empirically-derived subtypes of mild cognitive impairment consistent with conventional subtypes? *J Int Neuropsychol Soc.* 2013; 19:635–645. [PubMed: 23552486]
18. Edmonds EC, Delano-Wood L, Clark LR, Jak AJ, Nation DA, McDonald CR, Libon DJ, Au R, Galasko D, Salmon DP, Bondi MW. Susceptibility of the conventional criteria for mild cognitive impairment to false-positive diagnostic errors. *Alzheimers Dement.* 2015; 11:415–424. [PubMed: 24857234]
19. Delano-Wood L, Abeles N, Sacco JM, Wierenga CE, Horne NR, Bozoki A. Regional white matter pathology in mild cognitive impairment: Differential influence of lesion type on neuropsychological functioning. *Stroke.* 2008; 39:794–799. [PubMed: 18258826]
20. Jak AJ, Bondi MW, Delano-Wood L, Wierenga C, Corey-Bloom J, Salmon DP, Delis DC. Quantification of five neuropsychological approaches to defining mild cognitive impairment. *Am J Geriatr Psychiatry.* 2009; 17:368–375. [PubMed: 19390294]
21. Tuokko, HA.; McDowell, I. An overview of mild cognitive impairment. In: Tuokko, HA.; Hultsch, DF., editors. *Mild Cognitive Impairment: International Perspectives.* Taylor & Francis; New York: 2006. p. 3-28.
22. Saxton J, Snitz BE, Lopez OL, Ives DG, Dunn LO, Fitzpatrick A, Carlson MC, Dekosky ST. Functional and cognitive criteria produce different rates of mild cognitive impairment and conversion to dementia. *J Neurol Neurosurg Psychiatry.* 2009; 80:737–743. [PubMed: 19279031]
23. Bondi MW, Jak AJ, Delano-Wood L, Jacobson MW, Delis DC, Salmon DP. Neuropsychological contributions to the early identification of Alzheimer's disease. *Neuropsychol Rev.* 2008; 18:73–90. [PubMed: 18347989]
24. Kok E, Haikonen S, Luoto T, Huhtala H, Goebeler S, Haapasalo H, Karhunen PJ. Apolipoprotein E-dependent accumulation of Alzheimer disease-related lesions begins in middle age. *Ann Neurol.* 2009; 65:650–657. [PubMed: 19557866]
25. Joshi AD, Pontecorvo MJ, Clark CM, Carpenter AP, Jennings DL, Sadowsky CH, Adler LP, Kovnat KD, Seibyl JP, Arora A, Saha K, Burns JD, Lowrey MJ, Mintun MA, Skovronsky DM. Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects. *J Nucl Med.* 2012; 53:378–384. [PubMed: 22331215]
26. Landau SM, Breault C, Joshi AD, Pontecorvo M, Mathis CA, Jagust WJ, Mintun MA. Amyloid-beta imaging with Pittsburgh compound B and florbetapir: Comparing radiotracers and quantification methods. *J Nucl Med.* 2013; 54:70–77. [PubMed: 23166389]
27. Fleisher AS, Chen K, Liu X, Ayutyanont N, Roontiva A, Thiyyagura P, Protas H, Joshi AD, Sabbagh M, Sadowsky CH, Sperling RA, Clark CM, Mintun MA, Pontecorvo MJ, Coleman RE, Doraiswamy PM, Johnson KA, Carpenter AP, Skovronsky DM, Reiman EM. Apolipoprotein E epsilon4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease. *Neurobiol Aging.* 2013; 34:1–12. [PubMed: 22633529]
28. Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W, Ayutyanont N, Keppler J, Reeder SA, Langbaum JB, Alexander GE, Klunk WE, Mathis CA, Price JC, Aizenstein HJ, DeKosky ST, Caselli RJ. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. *Proc Natl Acad Sci U S A.* 2009; 106:6820–6825. [PubMed: 19346482]
29. Resnick SM, Bilgel M, Moghekar A, An Y, Cai Q, Wang MC, Thambisetty M, Prince JL, Zhou Y, Soldan A, Wong DF, O'Brien RJ, Ferrucci L, Albert MS. Changes in Abeta biomarkers and associations with APOE genotype in 2 longitudinal cohorts. *Neurobiol Aging.* 2015; 36:2333–2339. [PubMed: 26004017]
30. Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FR, Visser PJ, Aalten P, Aarsland D, Alcolea D, Alexander M, Almdahl IS, Arnold SE, Baldeiras I, Barthel H, van Berckel BN, Bibeau K, Blennow K, Brooks DJ, van Buchem MA, Camus V, Cavado E, Chen K, Chetelat G, Cohen AD, Drzezga A, Engelborghs S, Fagan AM, Fladby T, Fleisher AS, van der Flier WM, Ford L, Forster S, Fortea J, Foskett N, Frederiksen KS, Freund-Levi Y, Frisoni GB, Froelich L, Gabryelewicz T, Gill KD, Gkatzima O, Gomez-Tortosa E, Gordon MF, Grimmer T, Hampel H,

- Hausner L, Hellwig S, Herukka SK, Hildebrandt H, Ishihara L, Ivanoiu A, Jagust WJ, Johannsen P, Kandimalla R, Kapaki E, Klimkowicz-Mrowiec A, Klunk WE, Kohler S, Koglin N, Kornhuber J, Kramberger MG, Van Laere K, Landau SM, Lee DY, de Leon M, Lisetti V, Lleo A, Madsen K, Maier W, Marcusson J, Mattsson N, de Mendonca A, Meulenbroek O, Meyer PT, Mintun MA, Mok V, Molinuevo JL, Mollergerd HM, Morris JC, Mroczko B, Van der Mussele S, Na DL, Newberg A, Nordberg A, Nordlund A, Novak GP, Paraskevas GP, Parnetti L, Perera G, Peters O, Popp J, Prabhakar S, Rabinovici GD, Ramakers IH, Rami L, Resende de Oliveira C, Rinne JO, Rodrigue KM, Rodriguez-Rodriguez E, Roe CM, Rot U, Rowe CC, Ruther E, Sabri O, Sanchez-Juan P, Santana I, Sarazin M, Schroder J, Schutte C, Seo SW, Soetewey F, Soininen H, Spiru L, Struyfs H, Teunissen CE, Tsolaki M, Vandenberghe R, Verbeek MM, Villemagne VL, Vos SJ, van Waalwijk van Doorn LJ, Waldemar G, Wallin A, Wallin AK, Wiltfang J, Wolk DA, Zboch M, Zetterberg H. Prevalence of cerebral amyloid pathology in persons without dementia: A meta-analysis. *JAMA*. 2015; 313:1924–1938. [PubMed: 25988462]
31. Villemagne VL, Pike KE, Chetelat G, Ellis KA, Mulligan RS, Bourgeat P, Ackermann U, Jones G, Szoek C, Salvado O, Martins R, O’Keefe G, Mathis CA, Klunk WE, Ames D, Masters CL, Rowe CC. Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. *Ann Neurol*. 2011; 69:181–192. [PubMed: 21280088]
 32. Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. *Neurology*. 2007; 69:2197–2204. [PubMed: 17568013]
 33. Nettiksimmons J, DeCarli C, Landau S, Beckett L. Biological heterogeneity in ADNI amnesic mild cognitive impairment. *Alzheimers Dement*. 2014; 10:511–521. e511. [PubMed: 24418061]
 34. Ossenkoppele R, Jansen WJ, Rabinovici GD, Knol DL, van der Flier WM, van Berckel BN, Scheltens P, Visser PJ, Verfaillie SC, Zwan MD, Adriaanse SM, Lammertsma AA, Barkhof F, Jagust WJ, Miller BL, Rosen HJ, Landau SM, Villemagne VL, Rowe CC, Lee DY, Na DL, Seo SW, Sarazin M, Roe CM, Sabri O, Barthel H, Koglin N, Hodges J, Leyton CE, Vandenberghe R, van Laere K, Drzezga A, Forster S, Grimmer T, Sanchez-Juan P, Carril JM, Mok V, Camus V, Klunk WE, Cohen AD, Meyer PT, Hellwig S, Newberg A, Frederiksen KS, Fleisher AS, Mintun MA, Wolk DA, Nordberg A, Rinne JO, Chetelat G, Lleo A, Blesa R, Fortea J, Madsen K, Rodrigue KM, Brooks DJ. Prevalence of amyloid PET positivity in dementia syndromes: A meta-analysis. *JAMA*. 2015; 313:1939–1949. [PubMed: 25988463]
 35. Bangen KJ, Nation DA, Delano-Wood L, Weissberger GH, Hansen LA, Galasko DR, Salmon DP, Bondi MW. Aggregate effects of vascular risk factors on cerebrovascular changes in autopsy-confirmed Alzheimer’s disease. *Alzheimers Dement*. 2015; 11:394–403. e391. [PubMed: 25022538]
 36. Drachman DA. The amyloid hypothesis, time to move on: Amyloid is the downstream result, not cause, of Alzheimer’s disease. *Alzheimers Dement*. 2014; 10:372–380. [PubMed: 24589433]
 37. Morris GP, Clark IA, Vissel B. Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer’s disease. *Acta Neuropathol Commun*. 2014; 2:135. [PubMed: 25231068]
 38. Balasubramanian AB, Kawas CH, Peltz CB, Brookmeyer R, Corrada MM. Alzheimer disease pathology and longitudinal cognitive performance in the oldest-old with no dementia. *Neurology*. 2012; 79:915–921. [PubMed: 22895581]
 39. Bennett DA, Schneider JA, Bienias JL, Evans DA, Wilson RS. Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. *Neurology*. 2005; 64:834–841. [PubMed: 15753419]
 40. Davis DG, Schmitt FA, Wekstein DR, Markesbery WR. Alzheimer neuropathologic alterations in aged cognitively normal subjects. *J Neuropathol Exp Neurol*. 1999; 58:376–388. [PubMed: 10218633]
 41. Price JL, McKeel DW Jr, Buckles VD, Roe CM, Xiong C, Grundman M, Hansen LA, Petersen RC, Parisi JE, Dickson DW, Smith CD, Davis DG, Schmitt FA, Markesbery WR, Kaye J, Kurlan R, Hulette C, Kurland BF, Higdon R, Kukull W, Morris JC. Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease. *Neurobiol Aging*. 2009; 30:1026–1036. [PubMed: 19376612]

42. Rodrigue KM, Kennedy KM, Devous MD Sr, Rieck JR, Hebrank AC, Diaz-Arrastia R, Mathews D, Park DC. beta-Amyloid burden in healthy aging: Regional distribution and cognitive consequences. *Neurology*. 2012; 78:387–395. [PubMed: 22302550]
43. Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, Cowie TF, Dickinson KL, Maruff P, Darby D, Smith C, Woodward M, Merory J, Tochon-Danguy H, O'Keefe G, Klunk WE, Mathis CA, Price JC, Masters CL, Villemagne VL. Imaging beta-amyloid burden in aging and dementia. *Neurology*. 2007; 68:1718–1725. [PubMed: 17502554]
44. Gomez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, Parisi JE, Hyman BT. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. *Ann Neurol*. 1997; 41:17–24. [PubMed: 9005861]
45. Tokuda T, Ikeda S, Yanagisawa N, Ihara Y, Glenner GG. Re-examination of ex-boxers' brains using immunohistochemistry with antibodies to amyloid beta-protein and tau protein. *Acta Neuropathol*. 1991; 82:280–285. [PubMed: 1759560]
46. Drachman DA. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 12–1999. A 67-year-old man with three years of dementia. *N Engl J Med*. 1999; 340:1269–1277. [PubMed: 10210712]
47. Terry, RD.; Masliah, E.; Hansen, LA. The neuropathology of Alzheimer disease and the structural basis of its cognitive alterations. In: Terry, RD.; Katz-man, R.; Bick, KL.; Sisodia, SS., editors. *Alzheimer disease*. Lippincott Williams & Wilkens; Philadelphia: 1999. p. 187-206.
48. Jack CR Jr, Wiste HJ, Weigand SD, Knopman DS, Vemuri P, Mielke MM, Lowe V, Senjem ML, Gunter JL, Machulda MM, Gregg BE, Pankratz VS, Rocca WA, Petersen RC. Age, sex, and APOE epsilon4 effects on memory, brain structure, and beta-amyloid across the adult life span. *JAMA Neurol*. 2015; 72:511–519. [PubMed: 25775353]
49. Bennett DA, Wilson RS, Schneider JA, Evans DA, Mendes de Leon CF, Arnold SE, Barnes LL, Bienias JL. Education modifies the relation of AD pathology to level of cognitive function in older persons. *Neurology*. 2003; 60:1909–1915. [PubMed: 12821732]
50. Sperling RA, Rentz DM, Johnson KA, Karlawish J, Donohue M, Salmon DP, Aisen P. The A4 study: Stopping AD before symptoms begin? *Sci Transl Med*. 2014; 6:228fs213.
51. Ferman TJ, Smith GE, Kantarci K, Boeve BF, Pankratz VS, Dickson DW, Graff-Radford NR, Wszolek Z, Van Gerpen J, Uitti R, Pedraza O, Murray ME, Aakre J, Parisi J, Knopman DS, Petersen RC. Nonamnesic mild cognitive impairment progresses to dementia with Lewy bodies. *Neurology*. 2013; 81:2032–2038. [PubMed: 24212390]




Fig. 1. Mean z-scores for the three MCI subgroups on neuropsychological measures included in the cluster analysis of conventional Petersen/Winblad ADNI criteria. Error bars denote standard error of the mean.




Fig. 2. Distribution of amyloid positivity for the three MCI subgroups and normal controls based on the recommended threshold for cross-sectional florbetapir analyses of 1.11 using the whole cerebellum as the reference region.




Fig. 3. Distribution of mean cortical amyloid standard uptake value ratios (SUVRs) for the three MCI subgroups and normal controls.




Fig. 4. Mean cortical and regional florbetapir standard uptake value ratios (SUVRs) for MCI and cognitively normal groups. Error bars denote standard error of the mean. Symbols denote significant ($p < 0.008$) pairwise comparisons: Amnestic MCI versus Cluster Derived Normal; ^ Amnestic MCI versus Normal Controls; φ Dysexecutive/Mixed MCI versus Cluster Derived Normal; * Dysexecutive/Mixed MCI versus Normal Controls; # Amnestic MCI versus Dysexecutive/Mixed MCI; No significant Cluster Derived Normal versus Normal Controls findings were observed. All models were adjusted for age and APOE genotype ($\epsilon 4$ carrier versus noncarrier).




Fig. 5. Interaction of cognitive status (Amnestic MCI, Dysexecutive/Mixed MCI, Cluster-Derived Normal, Normal Control) and APOE genotype ($\epsilon 4$ carrier versus noncarrier) on regional florbetapir standard uptake value ratios (SUVRs). Error bars denote standard error of the mean. * $p < 0.008$

Table 1

Demographic and amyloid characteristics of the cluster and normal control groups

	Amnesic MCI (<i>n</i> = 227)	Dysexecutive MCI (<i>n</i> = 37)	Cluster-Derived Normal (<i>n</i> = 180)	Normal Control (<i>n</i> = 139)	<i>F</i> or χ^2	Sig.	Effect Size
<i>Demographics*</i>							
	Mean (SD)						
Age (years)	71.79 (7.06)	74.78 (8.47)	70.68 (7.78)	73.61 (6.09)	<i>F</i> = 6.27	<i>p</i> < 0.001	η_p^2 = 0.031
Education (years)	16.00 (2.66)	15.97 (2.87)	16.50 (2.59)	16.69 (2.53)	<i>F</i> = 2.52	<i>p</i> = 0.057	η_p^2 = 0.013
Sex (% male)	59.9%	62.2%	47.8%	51.1%	χ^2 = 7.47	<i>p</i> = 0.058	ϕ = 0.113
APOE $\epsilon 4$ (% yes)	53.3%	62.2%	38.9%	27.3%	χ^2 = 30.48	<i>p</i> < 0.001	ϕ = 0.229
Amyloid Positive (% yes)	63.0%	78.4%	41.7%	33.8%	χ^2 = 46.78	<i>p</i> < 0.001	ϕ = 0.283
<i>Regional Amyloid#</i>							
Cortical Summary	1.24 (0.22)	1.37 (0.24)	1.15 (0.19)	1.12 (0.19)	<i>F</i> = 13.34	<i>p</i> < 0.001	η_p^2 = 0.065
Frontal	1.24 (0.24)	1.37 (0.25)	1.13 (0.20)	1.10 (0.19)	<i>F</i> = 14.59	<i>p</i> < 0.001	η_p^2 = 0.070
Cingulate	1.34 (0.24)	1.43 (0.26)	1.24 (0.20)	1.21 (0.20)	<i>F</i> = 9.36	<i>p</i> < 0.001	η_p^2 = 0.046
Parietal	1.24 (0.22)	1.39 (0.25)	1.15 (0.20)	1.12 (0.20)	<i>F</i> = 13.61	<i>p</i> < 0.001	η_p^2 = 0.066
Temporal	1.15 (0.20)	1.29 (0.24)	1.06 (0.17)	1.04 (0.17)	<i>F</i> = 14.30	<i>p</i> < 0.001	η_p^2 = 0.069
<i>Clinical Outcome^A</i>							
Progression (MCI to dementia)	28 (13.5%)	11 (30.6%)	2 (1.2%)	n/a	χ^2 = 32.45	<i>p</i> < 0.001	ϕ = 0.288
Reversion (MCI to cognitively normal)	4 (1.9%)	1 (2.8%)	11 (6.7%)	n/a	χ^2 = 4.23	<i>p</i> = 0.121	ϕ = 0.108

* Data are summarized as mean (standard deviation), unless otherwise indicated;

units are standardized uptake value ratio (SUVR) with whole cerebellum (gray and white) as reference region and models are adjusted for age and APOE genotype ($\epsilon 4$ carrier versus noncarrier);

^A Number of participants for progression/reversion analysis: amnesic MCI: *n* = 207; dysexecutive/mixed MCI: *n* = 36; and cluster-derived normal: *n* = 164. Follow-up ranged from 6–36 months. Clinical outcome was not assessed for the Normal Control group given that they were selected on the basis of remaining cognitively normal (did not progress to MCI) throughout the course of their ADNI participation.